Oncolys BioPharma, Inc. AI Stock Analysis
Want to see JP:4588 full AI Analyst Report?
Oncolys BioPharma, Inc. (4588) AI Stock Analysis
Oncolys BioPharma, Inc.
(TSE/TYO:4588)
The overall score is 51, reflecting a sharp divide between strong market momentum and weak fundamentals. The stock's price is surging based on technical strength, but this is not supported by financials, as the company has minimal revenue, large losses, and a high cash burn rate. The negative P/E ratio further underscores the lack of current earnings. The primary risk is that the positive technical trend reverses if the company's financial position does not improve.
Oncolys BioPharma, Inc. (4588) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 247.60B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.75M
- Price to Earnings (P/E)
- -146.1
- Beta (1Y)
- 1.96
- Revenue Growth
- 1748.97%
- EPS Growth
- 35.11%
- Country
- Japan
- Employees
- 42
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Oncolys BioPharma, Inc. Business Overview & Revenue Model
Company Description
Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the Unit...
How the Company Makes Money
Detailed, company-specific revenue breakdown (e.g., product sales by drug, recurring service revenue, or disclosed milestone/royalty structures) is not available in the information provided here; therefore, this data point is null.
Oncolys BioPharma, Inc. Financial Statement Overview
Summary
Financial performance is critically weak. Revenue has collapsed to near zero (JPY 28.5M) with large net losses (JPY 2.1B). Operating cash flow is deeply negative, burning ~JPY 1.9B annually. The only support is a solid balance sheet with JPY 4.0B in equity and low debt, but this is being rapidly depleted.
Income Statement
10Very NegativeBalance Sheet
60NeutralCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.55M | 28.55M | 31.38M | 63.04M | 976.18M | 642.49M |
| Gross Profit | 28.30M | 28.30M | 31.38M | 30.61M | 338.49M | 198.80M |
| EBITDA | -2.05B | -2.05B | -1.68B | -1.93B | -1.14B | -1.60B |
| Net Income | -2.06B | -2.06B | -1.68B | -1.94B | -1.15B | -1.62B |
Balance Sheet | ||||||
| Total Assets | 4.56B | 4.56B | 3.20B | 2.04B | 2.65B | 4.29B |
| Cash, Cash Equivalents and Short-Term Investments | 3.72B | 3.72B | 2.41B | 1.53B | 1.71B | 3.45B |
| Total Debt | 320.02M | 320.02M | 324.64M | 315.17M | 393.66M | 503.47M |
| Total Liabilities | 555.91M | 555.91M | 446.65M | 566.50M | 491.69M | 697.88M |
| Stockholders Equity | 4.00B | 4.00B | 2.75B | 1.47B | 2.16B | 3.59B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.94B | -2.02B | -1.34B | -1.72B | -1.74B |
| Operating Cash Flow | 0 | -1.94B | -2.02B | -1.34B | -1.72B | -1.74B |
| Investing Cash Flow | 0 | -7.58M | -4.71M | -5.39M | 20.12M | -942.00K |
| Financing Cash Flow | 0 | 3.22B | 2.88B | 1.14B | -113.83M | 3.09B |
Oncolys BioPharma, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4588, the sentiment is Positive. The current price of 8410.00 is above the 20-day moving average (MA) of 6932.00, above the 50-day MA of 6174.20, and above the 200-day MA of 3521.32, indicating a bullish trend. The MACD of 589.20 indicates Negative momentum. The RSI at 65.28 is Neutral, neither overbought nor oversold. The STOCH value of 70.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4588.
Oncolys BioPharma, Inc. Peers Comparison
Overall Rating
JP:458851Neutral
JP:458349Neutral
JP:458748Neutral
JP:456441Neutral
JP:457539Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 51Neutral | JPY 248.42B | -146.15 | ― | ― | 1748.97% | 35.11% | |
| 49Neutral | JPY 6.30B | -6.28 | ― | ― | -13.40% | 7.50% | |
| 48Neutral | JPY 138.26B | -47.73 | -5.85% | ― | 14.25% | 50.07% | |
| 41Neutral | JPY 6.53B | -6.96 | -42.81% | ― | -25.56% | 17.01% | |
| 39Underperform | JPY 13.94B | -10.04 | ― | ― | ― | -12.48% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4588 | Oncolys BioPharma, Inc. | 8410.00 | 7342.00 | 687.45% | |
| JP:4587 | Peptidream | 1065.00 | -518.50 | -32.74% | |
| JP:4564 | OncoTherapy Science, Inc. | 16.00 | -7.00 | -30.43% | |
| JP:4575 | CanBas Co., Ltd. | 705.00 | -84.00 | -10.65% | |
| JP:4583 | Chiome Bioscience Inc. | 77.00 | -46.00 | -37.40% |
Oncolys BioPharma, Inc. Corporate Events
Oncolys BioPharma Reports Higher Sales and Narrower Nine-Month Loss
Oncolys BioPharma reported net sales of ¥527 million for the nine months ended September 30, 2026, up from ¥28 million a year earlier. Operating loss narrowed to ¥1.104 billion from ¥1.571 billion, while net loss improved to ¥1.115 billion from ¥1.61...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 19, 2026
